Targeted radiotherapy with gold nanoparticles: Current status and future perspectives

Nanomedicine

Volumn 9, Issue 7, 2014, Pages 1063-1082

  Ngwa, Wilfred ^a   Kumar, Rajiv ^a,b   Sridhar, Srinivas ^a,b   Korideck, Houari ^a   Zygmanski, Piotr ^a   Cormack, Robert A ^a   Berbeco, Ross ^a   Makrigiorgos, G Mike ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NORTHEASTERN UNIVERSITY   (United States)

Author keywords

cancer; gold nanoparticle; nanomedicine; radiotherapy; retinal disease

Indexed keywords

ANGIOGENESIS INHIBITOR; GOLD NANOPARTICLE; RADIOSENSITIZING AGENT; GOLD; METAL NANOPARTICLE;

BRACHYTHERAPY; CANCER RADIOTHERAPY; EXPERIMENTAL STUDY; HUMAN; PRIORITY JOURNAL; RADIOTHERAPY; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SUPERFICIAL RADIOTHERAPY; THEORETICAL STUDY; CHEMISTRY; NANOMEDICINE; NANOTECHNOLOGY; NEOPLASMS;

GOLD; HUMANS; METAL NANOPARTICLES; NANOMEDICINE; NANOTECHNOLOGY; NEOPLASMS;

EID: 84903825697     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.14.55     Document Type: Review

References (174)

1. Detappe A, Tsiamas P, Ngwa W, Zygmanski P, Makrigiorgos M, Berbeco R. The effect of flattening filter free delivery on endothelial dose enhancement with gold nanoparticles. Med. Phys. 40(3), 031706 (2013).
2. Tsiamas P, Liu B, Cifter F et al. Impact of beam quality on megavoltage radiotherapy treatment techniques utilizing gold nanoparticles for dose enhancement. Phys. Med. Biol. 58(3), 451-464 (2013).
3. Berbeco RI, Korideck H, Ngwa W et al. DNA damage enhancement from gold nanoparticles for clinical MV photon beams. Radiat. Res. 178(6), 604-608 (2012).
4. Ngwa W, Korideck H, Kassis AI et al. In vitro radiosensitization by gold nanoparticles during continuous low-dose-rate gamma irradiation with I-125 brachytherapy seeds. Nanomedicine 9(1), 25-27 (2013).
5. Chang JY, Zhang X, Wang X et al. Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in stage I or stage III non-small-cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 65(4), 1087-1096 (2006).
6. Begg AC, Stewart FA, Vens C. Strategies to improve radiotherapy with targeted drugs. Nat. Rev. Cancer 11(4), 239-253 (2011).
7. Barnett GC, West CM, Dunning AM et al. Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype. Nat. Rev. Cancer 9(2), 134-142 (2009).
8. Nguyen PL, D'Amico AV, Lee AK, Suh WW. Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: a systematic review of the literature. Cancer 110(7), 1417-1428 (2007). (Pubitemid 47463054)
9. Agarwal PK, Sadetsky N, Konety BR, Resnick MI, Carroll PR. Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes. Cancer 112(2), 307-314 (2008).
10. Westphalen AC, Coakley FV, Roach M 3rd, McCulloch CE, Kurhanewicz J. Locally recurrent prostate cancer after external beam radiation therapy: diagnostic performance of 1.5-T endorectal MR imaging and MR spectroscopic imaging for detection. Radiology 256(2), 485-492 (2010).
11. Stephenson AJ, Eastham JA. Role of salvage radical prostatectomy for recurrent prostate cancer after radiation therapy. J. Clin. Oncol. 23(32), 8198-8203 (2005).
12. Zelefsky MJ, Yamada Y, Fuks Z et al. Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. Int. J. Radiat. Oncol. Biol. Phys. 71(4), 1028-1033 (2008).
13. Pollack A, Hanlon AL, Horwitz EM, Feigenberg SJ, Uzzo RG, Hanks GE. Prostate cancer radiotherapy dose response: an update of the fox chase experience. J. Urol. 171(3), 1132-1136 (2004).
14. Al-Mamgani A, Van Putten WL, Heemsbergen WD et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 72(4), 980-988 (2008).
15. Al-Mamgani A, Van Putten WL, Van Der Wielen GJ, Levendag PC, Incrocci L. Dose escalation and quality of life in patients with localized prostate cancer treated with radiotherapy: long-term results of the Dutch randomized dose-escalation trial (CKTO 96-10 trial). Int. J. Radiat. Oncol. Biol. Phys. 79(4), 1004-1012 (2010).
16. Bachand F, Martin AG, Beaulieu L, Harel F, Vigneault E. An eight-year experience of HDR brachytherapy boost for localized prostate cancer: biopsy and PSA outcome. Int. J. Radiat. Oncol. Biol. Phys. 73(3), 679-684 (2009).
17. Nutting CM, Corbishley CM, Sanchez-Nieto B, Cosgrove VP, Webb S, Dearnaley DP. Potential improvements in the therapeutic ratio of prostate cancer irradiation: dose escalation of pathologically identified tumour nodules using intensity modulated radiotherapy. Br. J. Radiol. 75(890), 151-161 (2002). (Pubitemid 34256461)
18. Galvin JM, De Neve W. Intensity modulating and other radiation therapy devices for dose painting. J. Clin. Oncol. 25(8), 924-930 (2007).
19. Kuban DA, Levy LB, Cheung MR et al. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease? Int. J. Radiat. Oncol. Biol. Phys. 79(5), 1310-1317 (2011).
20. Heier JS, Boyer DS, Ciulla TA et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular agerelated macular degeneration: year 1 results of the FOCUS study. Arch. Ophthalmol. 124(11), 1532-1542 (2006). (Pubitemid 44748725)
21. Peeters ST, Heemsbergen WD, Van Putten WL et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int. J. Radiat. Oncol. Biol. Phys. 61(4), 1019-1034 (2005). (Pubitemid 40340897)
22. Litzenberg DW, Balter JM, Hadley SW et al. Influence of intrafraction motion on margins for prostate radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 65(2), 548-553 (2006).
23. Li HS, Chetty IJ, Enke CA et al. Dosimetric consequences of intrafraction prostate motion. Int. J. Radiat. Oncol. Biol. Phys. 71(3), 801-812 (2008).
24. Sovik A, Malinen E, Olsen DR. Strategies for biologic image-guided dose escalation: a review. Int. J. Radiat. Oncol. Biol. Phys. 73(3), 650-658 (2009).
25. Burri RJ, Stone NN, Unger P, Stock RG. Long-term outcome and toxicity of salvage brachytherapy for local failure after initial radiotherapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 77(5), 1338-1344 (2010).
26. Allen GW, Howard AR, Jarrard DF, Ritter MA. Management of prostate cancer recurrences after radiation therapy-brachytherapy as a salvage option. Cancer 110(7), 1405-1416 (2007). (Pubitemid 47463053)
27. Ng CK, Touma NJ, Chalasani V, Moussa M, Downey DB, Chin JL. The pattern of prostate cancer local recurrence after radiation and salvage cryoablation. Can. Urol. Assoc. J. 5(6), E125-128 (2011).
28. Nguyen PL, Chen RC, Clark JA et al. Patient-reported quality of life after salvage brachytherapy for radiorecurrent prostate cancer: a prospective Phase II study. Brachytherapy 8(4), 345-352 (2009).
29. Beyer DC. Salvage brachytherapy after external-beam irradiation for prostate cancer. Oncology 18(2), 151-158 (2004).
30. Beyer DC. Brachytherapy for recurrent prostate cancer after radiation therapy. Semin. Radiat. Oncol. 13(2), 158-165 (2003). (Pubitemid 36547493)
31. Trock BJ, Han M, Freedland SJ et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 299(23), 2760-2769 (2008). (Pubitemid 351846851)
32. Zelefsky MJ, Fuks Z, Wolfe T et al. Locally advanced prostatic cancer: long-term toxicity outcome after threedimensional conformal radiation therapy - a dose-escalation study. Radiology 209(1), 169-174 (1998). (Pubitemid 28464663)
33. Keall PJ, Mageras GS, Balter JM et al. The management of respiratory motion in radiation oncology report of AAPM Task Group 76. Med. Phys. 33(10), 3874-3900 (2006). (Pubitemid 44505111)
34. Herold DM, Das IJ, Stobbe CC, Iyer RV, Chapman JD. Gold microspheres: a selective technique for producing biologically effective dose enhancement. Int. J. Radiat. Biol. 76(10), 1357-1364 (2000).
35. Hainfeld JF, Slatkin DN, Smilowitz HM. The use of gold nanoparticles to enhance radiotherapy in mice. Phys. Med. Biol. 49(18), N309-N315 (2004). (Pubitemid 39302700)
36. Cheung JY, Tang FH. The calculation of dose enhancement close to platinum implants for skull radiography. Health Phys. 93(4), 267-272 (2007). (Pubitemid 350195161)
37. Lasagna-Reeves C, Gonzalez-Romero D, Barria MA et al. Bioaccumulation and toxicity of gold nanoparticles after repeated administration in mice. Biochem. Biophys. Res. Commun. 393(4), 649-655 (2010).
38. Mukherjee P, Bhattacharya R, Wang P et al. Antiangiogenic properties of gold nanoparticles. Clin. Cancer Res. 11(9), 3530-3534 (2005). (Pubitemid 40627908)
39. Shukla R, Bansal V, Chaudhary M, Basu A, Bhonde RR, Sastry M. Biocompatibility of gold nanoparticles and their endocytotic fate inside the cellular compartment: a microscopic overview. Langmuir 21(23), 10644-10654 (2005). (Pubitemid 41692144)
40. Connor EE, Mwamuka J, Gole A, Murphy CJ, Wyatt MD. Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity. Small 1(3), 325-327 (2005). (Pubitemid 43951781)
41. Hainfeld JF, Slatkin DN, Focella TM, Smilowitz HM. Gold nanoparticles: a new x-ray contrast agent. Br. J. Radiol. 79(939), 248-253 (2006).
42. Jain S, Hirst DG, O'Sullivan JM. Gold nanoparticles as novel agents for cancer therapy. The Br. J. Radiol. 85(1010), 101-113 (2012).
43. Hainfeld JF, Smilowitz HM, O'Connor MJ, Dilmanian FA, Slatkin DN. Gold nanoparticle imaging and radiotherapy of brain tumors in mice. Nanomedicine (Lond) 8(10), 1601-1609 (2013).
44. Kumar R, Korideck H, Ngwa W, Berbeco RI, Makrigiorgos GM, Sridhar S. Third generation gold nanoplatform optimized for radiation therapy. Transl. Cancer Res. 2(4), (2013).
45. Hainfeld JF, Dilmanian FA, Slatkin DN, Smilowitz HM. Radiotherapy enhancement with gold nanoparticles. J. Pharm. Pharmacol. 60(8), 977-985 (2008).
46. Hainfeld JF, Dilmanian FA, Zhong Z, Slatkin DN, Kalef- Ezra JA, Smilowitz HM. Gold nanoparticles enhance the radiation therapy of a murine squamous cell carcinoma. Phys. Med. Biol. 55(11), 3045-3059 (2010).
47. Cho SH, Jones BL, Krishnan S. The dosimetric feasibility of gold nanoparticle-aided radiation therapy (GNRT) via brachytherapy using low-energy gamma-/x-ray sources. Phys. Med. Biol. 54(16), 4889-4905 (2009).
48. Roeske JC, Nunez L, Hoggarth M, Labay E, Weichselbaum RR. Characterization of the theorectical radiation dose enhancement from nanoparticles. Technol. Cancer Res. Treat. 6(5), 395-401 (2007). (Pubitemid 47613287)
49. Zhang SX, Gao J, Buchholz TA et al. Quantifying tumor-selective radiation dose enhancements using gold nanoparticles: a Monte Carlo simulation study. Biomed. Microdevice 11, 925-933 (2009).
50. Jones BL, Krishnan S, Cho SH. Estimation of microscopic dose enhancement factor around gold nanoparticles by Monte Carlo Calculations. Med. Phys. 37(7), 3809-3816 (2010).
51. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46(12 Pt 1), 6387-6392 (1986).
52. Perrault SD, Walkey C, Jennings T, Fischer HC, Chan WC. Mediating tumor targeting efficiency of nanoparticles through design. Nano Lett. 9(5), 1909-1915 (2009).
53. Decuzzi P, Pasqualini R, Arap W, Ferrari M. Intravascular delivery of particulate systems: does geometry really matter? Pharm. Res. 26(1), 235-243 (2009).
54. Decuzzi P, Ferrari M. The adhesive strength of nonspherical particles mediated by specific interactions. Biomaterials 27(30), 5307-5314 (2006). (Pubitemid 44080296)
55. Chithrani DB, Jelveh S, Jalali F et al. Gold nanoparticles as radiation sensitizers in cancer therapy. Radiat. Res. 173(6), 719-728 (2010).
56. Zhang XD, Wu D, Shen X et al. Size-dependent radiosensitization of PEG-coated gold nanoparticles for cancer radiation therapy. Biomaterials 33(27), 6408-6419 (2012).
57. Champion JA, Katare YK, Mitragotri S. Making polymeric micro- and nanoparticles of complex shapes. Proc. Natl Acad. Sci. USA 104(29), 11901-11904 (2007). (Pubitemid 47185602)
58. Geng Y, Dalhaimer P, Cai S et al. Shape effects of filaments versus spherical particles in flow and drug delivery. Nat. Nanotechnol. 2(4), 249-255 (2007). (Pubitemid 46739812)
59. Nishiyama N. Nanomedicine: nanocarriers shape up for long life. Nat. Nanotechnol. 2(4), 203-204 (2007). (Pubitemid 46739817)
60. Champion JA, Katare YK, Mitragotri S. Particle shape: a new design parameter for micro- and nanoscale drug delivery carriers. J. Control. release 121(1-2), 3-9 (2007). (Pubitemid 47126059)
61. Tan J, Shah S, Thomas A, Ou-Yang HD, Liu Y. The influence of size, shape and vessel geometry on nanoparticle distribution. Microfluid. Nanofluidics 14(1-2), 77-87 (2013).
62. Wong C, Stylianopoulos T, Cui J et al. Multistage nanoparticle delivery system for deep penetration into tumor tissue. Proc. Natl Acad. Sci. USA 108(6), 2426-2431 (2011).
63. Huang K, Ma H, Liu J et al. Size-dependent localization and penetration of ultrasmall gold nanoparticles in cancer cells, multicellular spheroids, and tumors in vivo. ACS Nano. 6(5), 4483-4493 (2012).
64. Chithrani BD, Ghazani AA, Chan WC. Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. Nano Lett. 6(4), 662-668 (2006).
65. Chithrani DB. Intracellular uptake, transport, and processing of gold nanostructures. Mol. Membr. Biol. 27(7), 299-311 (2010).
66. Chithrani BD, Chan WC. Elucidating the mechanism of cellular uptake and removal of protein-coated gold nanoparticles of different sizes and shapes. Nano Lett. 7(6), 1542-1550 (2007). (Pubitemid 47140422)
67. Caldorera-Moore M, Guimard N, Shi L, Roy K. Designer nanoparticles: incorporating size, shape and triggered release into nanoscale drug carriers. Expert Opin. Drug Deliv. 7(4), 479-495 (2010).
68. Chithrani DB. Nanoparticles for improved therapeutics and imaging in cancer therapy. Recent Pat. Nanotechnol. 4(3), 171-180 (2010).
69. Hauck TS, Ghazani AA, Chan WC. Assessing the effect of surface chemistry on gold nanorod uptake, toxicity, and gene expression in mammalian cells. Small 4(1), 153-159 (2008). (Pubitemid 351205749)
70. Zhang G, Yang Z, Lu W et al. Influence of anchoring ligands and particle size on the colloidal stability and in vivo biodistribution of polyethylene glycolcoated gold nanoparticles in tumor-xenografted mice. Biomaterials 30(10), 1928-1936 (2009).
71. Choi CH, Alabi CA, Webster P, Davis ME. Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles. Proc. Natl Acad. Sci. USA 107(3), 1235-1240 (2010).
72. Yao L, Daniels J, Moshnikova A et al. pHLIP peptide targets nanogold particles to tumors. Proc. Natl Acad. Sci. USA 110(2), 465-470 (2013).
73. Weissleder R, Kelly K, Sun EY, Shtatland T, Josephson L. Cell-specific targeting of nanoparticles by multivalent attachment of small molecules. Nat. Biotechnol. 23(11), 1418-1423 (2005). (Pubitemid 41679395)
74. Kang B, Mackey MA, El-Sayed MA. Nuclear targeting of gold nanoparticles in cancer cells induces DNA damage, causing cytokinesis arrest and apoptosis. J. Am. Chem. Soc. 132(5), 1517-1519 (2010).
75. Sokolov K, Follen M, Aaron J et al. Real-time vital optical imaging of precancer using anti-epidermal growth factor receptor antibodies conjugated to gold nanoparticles. Cancer Res. 63(9), 1999-2004 (2003). (Pubitemid 36538596)
76. Brown SD, Nativo P, Smith J et al. Gold nanoparticles for the improved anticancer drug delivery of the active component of oxaliplatin. J. Am. Chem. Soc 132(13), 4678 (2010).
77. Dabbas S, Kaushik RR, Dandamudi S, Kuesters M, Campbell RB. Importance of the lipoosomal cationic lipid content and type in tumor vascular targeting: physicochemical characterization and in vitro studies using human promary and transformed endothelial cells. Endothelium 15, 189-201 (2008).
78. Cai W, Shin DW, Chen K et al. Peptide-labeled nearinfrared quantum dots for imaging tumor vasculature in living subjects. Nano Lett. 6(4), 669-676 (2006).
79. Diagaradjane P, Orenstein-Cardona JM, Colon- Casasnovas NE et al. Imaging epidermal growth factor receptor expression in vivo: pharmacokinetic and biodistribution characterization of a bioconjugated quantum dot nanoprobe. Clin. Cancer Res. 14(3), 731-741 (2008).
80. McCarthy JR, Weissleder R. Multifunctional magnetic nanoparticles for targeted imaging and therapy. Adv. Drug Deliv. Rev. 60(11), 1241-1251 (2008).
81. Qian X, Peng XH, Ansari DO et al. In vivo tumor targeting and spectroscopic detection with surface-enhanced Raman nanoparticle tags. Nat. Biotechnol. 26(1), 83-90 (2008).
82. Cheng Z, Al Zaki A, Hui JZ, Muzykantov VR, Tsourkas A. Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities. Science 338(6109), 903-910 (2012).
83. Grieneisen ML, Zhang M. Nanoscience and nanotechnology: evolving definitions and growing footprint on the scientific landscape. Small 7(20), 2836-2839 (2011).
84. Tripathi RM, Shrivastav A, Shrivastav BR. Biogenic gold nanoparticles: as a potential candidate for brain tumor directed drug delivery. Artif. Cells Nanomed. Biotechnol. (2014).
85. Pandey S, Mewada A, Thakur M, Shah R, Oza G, Sharon M. Biogenic gold nanoparticles as fotillas to fire berberine hydrochloride using folic acid as molecular road map. Mater. Sci. Eng. C Mater. Biol. Appl. 33(7), 3716-3722 (2013).
86. Lee SM, Kim HJ, Kim SY et al. Drug-loaded gold plasmonic nanoparticles for treatment of multidrug resistance in cancer. Biomaterials 35(7), 2272-2282 (2014).
87. Cheng Y, Doane TL, Chuang CH, Ziady A, Burda C. Near infrared light-triggered drug generation and release from gold nanoparticle carriers for photodynamic therapy. Small 10(9), 1799-1804 (2014).
88. Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat. Rev. Clin. Oncol. 7(11), 653-664 (2010).
89. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307(5706), 58-62 (2005). (Pubitemid 40093472)
90. Winkler F, Kozin SV, Tong RT et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6(6), 553-563 (2004). (Pubitemid 40017699)
91. Magzoub M, Jin S, Verkman AS. Enhanced macromolecule diffusion deep in tumors after enzymatic digestion of extracellular matrix collagen and its associated proteoglycan decorin. FASEB J. 22(1), 276-284 (2008).
92. Netti PA, Berk DA, Swartz MA, Grodzinsky AJ, Jain RK. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res. 60(9), 2497-2503 (2000). (Pubitemid 30262444)
93. Prabhakar U, Maeda H, Jain RK et al. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res. 73(8), 2412-2417 (2013).
94. Begum M, Abbulu K, Sudhakar M. Flurbiprofenloaded stealth liposomes: studies on the development, characterization, pharmacokinetics, and biodistribution. J. Young Pharm. 4(4), 209-219 (2012).
95. Harrington KJ, Mohammadtaghi S, Uster PS et al. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin. Cancer Res. 7(2), 243-254 (2001). (Pubitemid 32183025)
96. Zhang SX, Gao J, Buchholz TA et al. Quantifying tumor-selective radiation dose enhancements using gold nanoparticles: a Monte Carlo simulation study. Biomed. Microdevice 11, 925-933 (2009).
97. Ngwa W, Makrigiorgos GM, Berbeco RI. Applying gold nanoparticles as tumor-vascular disrupting agents during brachytherapy: estimation of endothelial dose enhancement. Phys. Med. Biol. 55(21), 6533-6548 (2010).
98. Ngwa W, Makrigiorgos GM, Berbeco RI. Gold nanoparticle-aided brachytherapy with vascular dose painting: estimation of dose enhancement to the tumor endothelial cell nucleus. Med. Phys. 39(1), 392-398 (2012).
99. Berbeco RI, Ngwa W, Makrigiorgos GM. Localized dose enhancement to tumor blood vessel endothelial cells via megavoltage x-rays and targeted gold nanoparticles: new potential for external beam radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 81(1), 270-276 (2011).
100. Ngwa W, Makrigiorgos GM, Berbeco RI. Gold nanoparticle enhancement of stereotactic radiosurgery for neovascular age-related macular degeneration. Phys. Med. Biol. 57(20), 6371-6380 (2012).
101. Lechtman E, Chattopadhyay N, Cai Z, Mashouf S, Reilly R, Pignol JP. Implications on clinical scenario of gold nanoparticle radiosensitization in regards to photon energy, nanoparticle size, concentration and location. Phys. Med. Biol. 56(15), 4631-4647 (2011).
102. Leung MK, Chow JC, Chithrani BD, Lee MJ, Oms B, Jaffray DA. Irradiation of gold nanoparticles by x-rays: Monte Carlo simulation of dose enhancements and the spatial properties of the secondary electrons production. Med. Phys. 38(2), 624-631 (2011).
103. Zygmanski P, Liu B, Tsiamas P et al. Dependence of Monte Carlo microdosimetric computations on the simulation geometry of gold nanoparticles. Phys. Med. Biol. 58(22), 7961-7977 (2013).
104. Rahman WN, Bishara N, Ackerly T et al. Enhancement of radiation effects by gold nanoparticles for superficial radiation therapy. Nanomedicine 5(2), 136-142 (2009).
105. Kong T, Zeng J, Wang X et al. Enhancement of radiation cytotoxicity in breast-cancer cells by localized attachment of gold nanoparticles. Small 4(9), 1537-1543 (2008).
106. Jain S, Coulter JA, Hounsell AR et al. Cell-specific radiosensitization by gold nanoparticles at megavoltage radiation energies. Int. J. Radiat. Oncol. Biol. Phys. 79(2), 531-539 (2011).
107. Liu CJ, Wang CH, Chen ST et al. Enhancement of cell radiation sensitivity by pegylated gold nanoparticles. Phys. Med. Biol. 55(4), 931-945 (2010).
108. Roa W, Zhang X, Guo L et al. Gold nanoparticle sensitize radiotherapy of prostate cancer cells by regulation of the cell cycle. Nanotechnology 20(37), 375101 (2009).
109. Butterworth KT, McMahon SJ, Taggart LE, Prise MK. Radiosensitization by gold nanoparticles: effective at megavoltage energies and potential role of oxidative stress. Transl. Cancer Res. 2(4), 269-279 (2013).
110. Butterworth KT, Coulter JA, Jain S et al. Evaluation of cytotoxicity and radiation enhancement using 1.9 nm gold particles: potential application for cancer therapy. Nanotechnology 21(29), 295101 (2010).
111. Misawa M, Takahashi J. Generation of reactive oxygen species induced by gold nanoparticles under x-ray and UV Irradiations. Nanomedicine 7(5), 604-614 (2011).
112. Pan Y, Leifert A, Ruau D et al. Gold nanoparticles of diameter 1.4 nm trigger necrosis by oxidative stress and mitochondrial damage. Small 5(18), 2067-2076 (2009).
113. Chompoosor A, Saha K, Ghosh PS et al. The role of surface functionality on acute cytotoxicity, ROS generation and DNA damage by cationic gold nanoparticles. Small 6(20), 2246-2249 (2010).
114. Al Zaki A, Joh D, Cheng Z. Gold-loaded polymeric micelles for computed tomography-guided radiation therapy treatment and radiosensitization. ACS Nano 8(1), 104-112 (2014).
115. Bobyk L, Edouard M, Deman P et al. Photoactivation of gold nanoparticles for glioma treatment. Nanomedicine 9(7), 1089-1097 (2013).
116. Joh DY, Sun L, Stangl M et al. Selective targeting of brain tumors with gold nanoparticle-induced radiosensitization. PLoS One 8(4), e62425 (2013).
117. Brun E, Sanche L, Sicard-Roselli C. Parameters governing gold nanoparticle x-ray radiosensitization of DNA in solution. Colloids Surf. B Biointerfaces 72(1), 128-134 (2009).
118. Ngwa W, Berbeco RI, Makrigiorgos GM. Gold nanoparticleaided brachytherapy with vascular dose painting: Estimation of dose enhancement to the tumor endothelial cell nucleus. Med. Phys. 39(1), 392-398 (2012).
119. Makrigiorgos GM, Adelstein SJ, Kassis AI. Cellular radiation dosimetry and its implications for estimation of radiation risks. Illustrative results with technetium 99m-labeled microspheres and macroaggregates. JAMA 264(5), 592-595 (1990). (Pubitemid 20241440)
120. Makrigiorgos GM, Ito S, Baranowska-Kortylewicz J et al. Inhomogeneous deposition of radiopharmaceuticals at the cellular level: experimental evidence and dosimetric implications. J. Nucl. Med 31(8), 1358-1363 (1990).
121. Denekamp J. Endothelial cell proliferation as a novel approach to targeting tumour therapy. Br. J. Cancer 45(1), 136-139 (1982). (Pubitemid 12207761)
122. Denekamp J. Vascular endothelium as the vulnerable element in tumours. Acta Radiol. Oncol. 23(4), 217-225 (1984). (Pubitemid 15072794)
123. Gridelli C, Rossi A, Maione P et al. Vascular disrupting agents: a novel mechanism of action in the battle against non-small cell lung cancer. Oncologist 14(6), 612-620 (2009).
124. Garcia-Barros M, Paris F, Cordon-Cardo C et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300(5622), 1155-1159 (2003). (Pubitemid 36583102)
125. Boerman OC, Sharkey RM, Blumenthal RD, Aninipot RL, Goldenberg DM. The presence of a concomitant bulky tumor can decrease the uptake and therapeutic efficacy of radiolabeled antibodies in small tumors. Int. J. Cancer 51(3), 470-475 (1992).
126. Siemann DW, Shi W. Targeting the tumor blood vessel network to enhance the efficacy of radiation therapy. Semin. Radiat. Oncol. 13(1), 53-61 (2003). (Pubitemid 36173260)
127. Cooney MM, Van Heeckeren W, Bhakta S, Ortiz J, Remick SC. Drug insight: vascular disrupting agents and angiogenesis - novel approaches for drug delivery. Nat. Clin. Pract. Oncol. 3(12), 682-692 (2006). (Pubitemid 44843126)
128. Skliarenko JV, Lunt SJ, Gordon ML, Vitkin A, Milosevic M, Hill RP. Effects of the vascular disrupting agent ZD6126 on interstitial fluid pressure and cell survival in tumors. Cancer Res. 66(4), 2074-2080 (2006).
129. Van Heeckeren WJ, Bhakta S, Ortiz J. Promise of new vascular-disrupting agents balanced with cardiac toxicity: is it time for oncologists to get to know their cardiologistsJ. Clin. Oncol. 24(10), 1485-1488 (2006). (Pubitemid 46638767)
130. Cormack RA, Sridhar S, Suh WW, D'Amico AV, Makrigiorgos GM. Biological in situ dose painting for image-guided radiation therapy using drug-loaded implantable devices. Int. J. Radiat. Oncol. Biol. Phys. 76(2), 615-623 (2010).
131. Nagesha DK, Tada DB, Stambaugh CK et al. Radiosensitizereluting nanocoatings on gold fiducials for biological in-situ image-guided radio therapy (BIS-IGRT). Phys. Med. Biol. 55(20), 6039-6052 (2010).
132. Dong Y, Chin SF, Blanco E et al. Intratumoral delivery of betalapachone via polymer implants for prostate cancer therapy. Clin. Cancer Res. 15(1), 131-139 (2009).
133. Qian F, Szymanski A, Gao J. Fabrication and characterization of controlled release poly(d,l-lactide-co-glycolide) millirods. J. Biomed. Mater. Res. 55(4), 512-522 (2001).
134. Takeda A, Baffi JZ, Kleinman ME et al. CCR3 is a target for age-related macular degeneration diagnosis and therapy. Nature 460(7252), 225-230 (2009).
135. Resnikoff S, Pascolini D, Etya'ale D et al. Global data on visual impairment in the year 2002. Bull. World Health Organ. 82(11), 844-851 (2004). (Pubitemid 39573742)
136. The Global Economic Cost of Visual Impairment. AMD Alliance International. London, UK (2010).
137. Axer-Siegel R, Ehrlich R, Yassur Y et al. Photodynamic therapy for age-related macular degeneration in a clinical setting: visual results and angiographic patterns. Am. J. Ophthalmol. 137(2), 258-264 (2004). (Pubitemid 38220997)
138. Yip PP, Woo CF, Tang HH, Ho CK. Triple therapy for neovascular age-related macular degeneration using singlesession photodynamic therapy combined with intravitreal bevacizumab and triamcinolone. Br. J. Ophthalmol. 93(6), 754-758 (2009).
139. Rosenfeld PJ, Brown DM, Heier JS et al. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 355(14), 1419-1431 (2006). (Pubitemid 44511557)
140. Ng EW, Adamis AP. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can. J. Ophthalmol. 40(3), 352-368 (2005). (Pubitemid 40942262)
141. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 116(1), 57-65 e55 (2009).
142. Bressler NM. Antiangiogenic approaches to age-related macular degeneration today. Ophthalmology 116(10 Suppl.), S15-S23 (2009).
143. Salehi-Had H, Roh MI, Giani A et al. Utilizing targeted gene therapy with nanoparticles binding alpha v beta 3 for imaging and treating choroidal neovascularization. PLoS One 6(4), e18864 (2011).
144. Petrarca R, Jackson TL. Radiation therapy for neovascular age-related macular degeneration. Clin. Ophthalmol. 5, 57-63 (2011).
145. Hanlon J, Lee C, Chell E et al. Kilovoltage stereotactic radiosurgery for age-related macular degeneration: assessment of optic nerve dose and patient effective dose. Med. Phys. 36(8), 3671-3681 (2009).
146. Moshfeghi DM, Kaiser PK, Gertner M. Stereotactic low-voltage x-ray irradiation for age-related macular degeneration. Br. J. Ophthalmol. 95(2), 185-188 (2011).
147. Fine SL, Maguire MG. It is not time to abandon radiotherapy for neovascular age-related macular degeneration. Arch. Ophthalmol. 119(2), 275-276 (2001). (Pubitemid 32147938)
148. Bonnaud S, Niaudet C, Pottier G et al. Sphingosine-1- phosphate protects proliferating endothelial cells from ceramide-induced apoptosis but not from DNA damageinduced mitotic death. Cancer Res. 67(4), 1803-1811 (2007). (Pubitemid 46389242)
149. Hanlon J, Firpo M, Chell E, Moshfeghi DM, Bolch WE. Stereotactic radiosurgery for AMD: a Monte Carlobased assessment of patient-specific tissue doses. Invest. Ophthalmol. Vis. Sci. 52(5), 2334-2342 (2011).
150. Taddei PJ, Chell E, Hansen S, Gertner M, Newhauser WD. Assessment of targeting accuracy of a low-energy stereotactic radiosurgery treatment for age-related macular degeneration. Phys. Med. Biol. 55(23), 7037-7054 (2010).
151. Canton VM, Quiroz-Mercado H, Velez-Montoya R et al. 16-Gy low-voltage x-ray irradiation with ranibizumab therapy for AMD: 6-month safety and functional outcomes. Ophthalmic Surg. Lasers Imaging 42(6), 468-473 (2011).
152. Moshfeghi AA, Canton VM, Quiroz-Mercado H et al. 16-Gy low-voltage x-ray irradiation followed by as-needed ranibizumab therapy for AMD: 6-month outcomes of a "radiation-first" strategy. Ophthalmic Surg. Lasers Imaging 42(6), 460-467 (2011).
153. Canton VM, Quiroz-Mercado H, Velez-Montoya R et al. 24-Gy low-voltage x-ray irradiation with ranibizumab therapy for neovascular AMD: 6-month safety and functional outcomes. Ophthalmic Surg. Lasers Imaging 43(1), 20-24 (2012).
154. Gokeri G, Kocar C, Tombakoglu M. Monte Carlo simulation of microbeam radiation therapy with an interlaced irradiation geometry and an Au contrast agent in a realistic head phantom. Phys. Med. Biol. 55(24), 7469-7487 (2010).
155. Van Den Heuvel F, Locquet JP, Nuyts S. Beam energy considerations for gold nano-particle enhanced radiation treatment. Phys. Med. Biol. 55(16), 4509-4520 (2010).
156. Garnica-Garza HM. Contrast-enhanced radiotherapy: feasibility and characteristics of the physical absorbed dose distribution for deep-seated tumors. Phys. Med. Biol. 54(18), 5411-5425 (2009).
157. Singh SR, Grossniklaus HE, Kang SJ, Edelhauser HF, Ambati BK, Kompella UB. Intravenous transferrin, RGD peptide and dual-targeted nanoparticles enhance anti-VEGF intraceptor gene delivery to laser-induced CNV. Gene Ther. 16(5), 645-659 (2009).
158. Iezzi R, Guru BR, Glybina IV, Mishra MK, Kennedy A, Kannan RM. Dendrimer-based targeted intravitreal therapy for sustained attenuation of neuroinflammation in retinal degeneration. Biomaterials 33(3), 979-988 (2012).
159. Kim JH, Kim KW, Kim MH, Yu YS. Intravenously administered gold nanoparticles pass through the blood- retinal barrier depending on the particle size, and induce no retinal toxicity. Nanotechnology 20(50), 505101 (2009).
160. Farjo KM, Ma JX. The potential of nanomedicine therapies to treat neovascular disease in the retina. J. Angiogenes Res. 2, 21 (2010).
161. Korideck H, Ngwa W, Makrigiorgos GM, Berbeco RI. The Quantification of gold nanoparticles as contrast agents for small animal volumetric studies. Int. J. Radiat. Oncol. Biol. Phys. 81(2 Suppl.), S887-S888 (2011).
162. Reuveni T, Motiei M, Romman Z, Popovtzer A, Popovtzer R. Targeted gold
163. Popovtzer R, Agrawal A, Kotov NA et al. Targeted gold nanoparticles enable molecular CT imaging of cancer. Nano Lett. 8(12), 4593-4596 (2008).
164. Mason RP, Zhao D, Liu L, Trawick ML, Pinney KG. A perspective on vascular disrupting agents that interact with tubulin: preclinical tumor imaging and biological assessment. Integr Biol (Camb) 3(4), 375-387 (2011).
165. Ricketts K, Guazzoni C, Castoldi A, Gibson AP, Royle GJ. An x-ray fluorescence imaging system for gold nanoparticle detection. Phys. Med. Biol. 58(21), 7841-7855 (2013).
166. Chang MY, Shiau AL, Chen YH, Chang CJ, Chen HH, Wu CL. Increased apoptotic potential and dose-enhancing effect of gold nanoparticles in combination with single-dose clinical electron beams on tumor-bearing mice. Cancer Sci. 99(7), 1479-1484 (2008). (Pubitemid 351761741)
167. Zheng Y, Hunting DJ, Ayotte P, Sanche L. Radiosensitization of DNA by gold nanoparticles irradiated with high-energy electrons. Radiat. Res. 169(1), 19-27 (2008).
168. Polf JC, Bronk LF, Driessen WH, Arap W, Pasqualini R, Gillin M. Enhanced relative biological effectiveness of proton radiotherapy in tumor cells with internalized gold nanoparticles. Applied Phys. Lett. 98(19), 193702 (2011).
169. Kim JK, Seo SJ, Kim HT et al. Enhanced proton treatment in mouse tumors through proton irradiated nanoradiator effects on metallic nanoparticles. Phys. Med. Biol. 57(24), 8309-8323 (2012).
170. Hebert EM, Debouttiere PJ, Lepage M, Sanche L, Hunting DJ. Preferential tumour accumulation of gold nanoparticles, visualised by magnetic resonance imaging: radiosensitisation studies in vivo and in vitro. Int. J. Radiat. Biol. 86(8), 692-700 (2010).
171. Hainfeld JF, O'Connor MJ, Lin P, Qian L, Slatkin DN, Smilowitz HM. Infrared-transparent gold nanoparticles converted by tumors to infrared absorbers cure tumors in mice by photothermal therapy. PLoS One 9(2), e88414 (2014).
172. Hossain M, Su M. Nanoparticle location and material dependent dose enhancement in x-ray radiation therapy. J. Phys. Chem. 116(43), 23047-23052 (2012).
173. Bahreyni Toossi MT, Ghorbani M, Mehrpouyan M, Akbari F, Sobhkhiz Sabet L, Soleimani Meigooni A. A Monte Carlo study on tissue dose enhancement in brachytherapy: a comparison between gadolinium and gold nanoparticles. Australas. Phys. Eng. Sci. Med. 35(2), 177-185 (2012).
174. Bernier J, Hall EJ, Giaccia A. Radiation oncology: a century of achievements. Nat. Rev. Cancer 4(9), 737-747 (2004). (Pubitemid 39215072)